Advances in New Technology Add-On Payments for Innovative Medicine in China’s DRG/DIP Framework
In July, China’s National Healthcare Security Administration introduced the CHS-DRG Grouping Plan (Version 2.0), expanding the number of
Capitalizing on Specialized Medical Services in China: Opportunities for Innovative Life Sciences Manufacturers
To take advantage of these opportunities, manufacturers must focus on three key success factors.
Three Key Trends Shaping Pricing for Innovative Non-VBP Medical Devices in China
Understanding and strategically applying these trends is crucial for optimizing pricing strategies and enhancing market adoption of innovative medical technologies in China.
Shanghai Pilots: Leading Value-Based and Risk-Sharing Reimbursement for Medical Consumables in China
Shanghai utilizes value-based pricing negotiations and performance-linked payments for medical consumable reimbursements, providing insights into the future direction of high-value medical consumable reimbursement under China's basic medical insurance.
China's Commercial Health Insurance Formulary Development: Current State and Future Directions
Executive Summary
The commercial health insurance sector in China presents substantial opportunities for growth, with the development of commercial insurance
Fostering Medical Innovation: How China's Social and Commercial Insurance Can Work Together
A healthy innovation ecosystem for medicines in China requires effective integration between basic and commercial health insurance. Success hinges on stakeholders operating within China's social security framework and focusing first on tackling the low-hanging fruit.
Impacts of Provincial Central Pooling of Basic Medical Insurance on China's Healthcare Ecosystem
Increasing the risk pooling level is essential for reducing regional disparities and improving the efficiency of BMI funds. This change will deeply affect the supply and demand sides of China's healthcare ecosystem.
Advancements in China's BMI Payment Policies for High-Value Medical Consumables: How MedTech Should Prepare
These policies create a national framework for the pricing and reimbursement of high-value medical consumables under basic medical insurance schemes, necessitating proactive preparedness from MedTech firms.
Quantifying Innovation: Three Key Signals from NHSA's Draft on New Chemical Drug Launch Pricing
The standout enhancement in the current proposal is the addition of a self-assessment scale. This tool, designed to assign a score that quantifies innovation quality based on the company's self-assessment, plays a crucial role in determining the initial pricing of their drugs.
